Katie Lahusen
Physician Assistant · Bend, ORNPI 1336601483
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,799 of the $8,913 with a category attached, or 87.5%. It is spread thinly across 41 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,449 and has fallen 81.0% since, to $655 in 2025. Among physician assistant clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $28.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Novo Nordisk$1K
- AbbVie$891
- Esperion Therapeutics, Inc.$749
- Amgen$738
- Lilly USA, LLC$507
- plus $3K from 35 others
What the payments were for
- Consulting fees$8009%
- Travel & lodging$2933%
- Food & beverage$7,79988%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,913 in reported general payments places this provider in the 95th percentile of 1,756 physician assistant providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 158 | $152,671 |
| JardianceEmpagliflozin | 109 | $131,310 |
| MounjaroTirzepatide | 100 | $121,421 |
| TrulicityDulaglutide | 88 | $81,857 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $36,424 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $29,550 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $15,032 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $12,522 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $7,738 |
| NovologInsulin Aspart | 25 | $7,540 |
| Novolog FlexpenInsulin Aspart | 37 | $6,609 |
| HumalogInsulin Lispro | 18 | $4,839 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,452 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $4,231 |
| VascepaIcosapent Ethyl | 11 | $3,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $507 | $208,117206 claims |
| Novo NordiskOzempic, Novolog | $1,067 | $160,211183 claims |
| Boehringer IngelheimJardiance | $97 | $131,310109 claims |
| AbbVieSynthroid, Armour Thyroid | $891 | $4,59961 claims |
| Sanofi-aventis U.S. LLCLantus | $53 | $3,34016 claims |
| IBSA Pharma Inc.Tirosint | $34 | $2,22411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,756 physician assistant providers in Oregon.
Other physician assistant in Bend
- Hanna TynerBend$12K
- Sarah AtkinBend$7K
- Tara HardingeBend$6K
- Rainie RogersBend$6K
- Kirsten HeronBend$5K
- Mitchell DavisBend$4K
- Devon ParksEugene$62K
- Ryan CainCorvallis$55K
- Sean BrownPortland$43K
- Meegan MangumPortland$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.